Search results for " Outcome"

showing 10 items of 4574 documents

Laparoscopic, three-port and SILS cholecystectomy: a retrospective study.

2014

Introduction. The aim of this study was to compare the results of classic laparoscopic, three-port and SILS cholecystectomy. Materials and methods. We conducted a retrospective study of da- ta collected between January 2010 and December 2012 pertaining to 159 selected patients with symptomatic gallstones. 57 underwent lapa- roscopic cholecystectomy, 51 three-port cholecystectomy and 48 SILS cholecystectomy. We then compared the groups with respect to mean ope- rating time, intraoperative complications, postoperative pain, duration of hospitalization and final aesthetic result. Introduction The first laparoscopic cholecystectomy was carried out in 1987 in France by Philippe Mouret (1). The p…

AdultAged 80 and overMaleAdolescentLength of StayMiddle AgedSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSettore MED/18 - Chirurgia GeneraleTreatment OutcomeCholecystectomy LaparoscopicSILS CHOLECYSTECTOMYCholelithiasisFeasibility StudiesHumansCholecystectomyFemaleOriginal ArticleAgedFollow-Up StudiesRetrospective Studies
researchProduct

A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-i…

2010

Abstract OBJECTIVE: To evaluate the efficacy of 1-year maintenance after a 6-week cycle of early intravesical chemotherapy, as the role of maintenance in intravesical chemotherapy is debated. PATIENTS AND METHODS: Between May 2002 and August 2003, 577 patients with non-muscle-invasive bladder cancer (NMI-BC) underwent transurethral resection (TUR) and early intravesical chemotherapy (epirubicin, 80 mg/50 mL). They were randomized between a 6-week induction cycle and the induction cycle plus maintenance with 10 monthly instillations. In all, 95 patients with T1G3, Tis or single and primary Ta-T1 G1-G2 tumours were excluded; 482 patients at intermediate risk of recurrence continued the study.…

AdultAged 80 and overMaleAntibiotics AntineoplasticRemission InductionCystoscopyintravesical chemotherapy bladder carcinomaMiddle AgedCombined Modality TherapySettore MED/24 - UrologiaAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsHumansFemaleNeoplasm Recurrence LocalEpidemiologic MethodsAgedEpirubicin
researchProduct

Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.

2011

To retrospectively assess the efficacy of bendamustine alone and with rituximab (R-B), 109 patients with relapsed chronic lymphocytic leukaemia (CLL) were enrolled in 24 Italian centres. The median age was 66 years (range 39-85). Forty-three percent of patients had relapsed and 57% were resistant (median previous therapies = 3; range 1-8). Twenty-two patients received bendamustine alone and 87 patients received R-B (median B dosage: 100 mg/m(2) per day, range 90-130 mg/m(2) per day). The overall response rate was 69·6% (complete response 28·6%; partial response 41%), and was significantly higher in patients treated with R-B (P = 0·014) and in those responsive to the previous treatment (P=0·…

AdultAged 80 and overMaleAntineoplastic AgentsMiddle AgedLeukemia Lymphocytic Chronic B-CellAntibodies Monoclonal Murine-DerivedTreatment OutcomeDrug Resistance NeoplasmRecurrenceAntineoplastic Combined Chemotherapy ProtocolsNitrogen Mustard CompoundsBendamustine HydrochlorideDrug EvaluationHumanschronic lymphocytic leukemiaFemaleChronic lymphocytic leukemia; bendamustineBendamustinaEpidemiologic MethodsRituximabAged
researchProduct

Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma

2017

Abstract Background Transarterial chemoembolisation is the standard of care for intermediate stage (BCLC B) hepatocellular carcinoma, but it is challenging to decide when to repeat or stop treatment. Here we performed the first external validation of the SNACOR (tumour Size and Number, baseline Alpha-fetoprotein, Child-Pugh and Objective radiological Response) risk prediction model. Methods A total of 1030 patients with hepatocellular carcinoma underwent transarterial chemoembolisation at our tertiary referral centre from January 2000 to December 2016. We determined the following variables that were needed to calculate the SNACOR at baseline: tumour size and number, alpha-fetoprotein level,…

AdultAged 80 and overMaleCarcinoma HepatocellularHepatocellular carcinomaLiver Neoplasms610 MedizinKaplan-Meier EstimateSNACORMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282Magnetic Resonance ImagingTreatment OutcomeTransarterial chemoembolisation610 Medical sciencesBiomarkers TumorHumansFemaleChemoembolization TherapeuticTomography X-Ray ComputedAgedNeoplasm StagingResearch Article
researchProduct

Does Preoperative Treatment with a Gonadotropin-Releasing Hormone Agonist Improve the Outcome of Endometrial Resection?

1998

Abstract Study Objective. To verify if more favorable long-term results of endometrial resection can be obtained with preoperative gonadotropin-releasing hormone (GnRH) agonist treatment. Design. Multicenter, randomized, controlled trial (Canadian Task Force classification I). Setting. Tertiary care academic department. Patients. Sixty-three premenopausal women with established menorrhagia. Intervention. Eight weeks of goserelin depot treatment before endometrial resection or immediate surgery in the early proliferative phase of the cycle. Measurements and Main Results. Variations in menstrual patterns and bleeding scores as well as overall degree of satisfaction with treatment were determi…

AdultAgonistmedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classlaw.inventionEndometriumRandomized controlled triallawGonadotropin-releasing hormone agonistPreoperative CareFollicular phaseElectrocoagulationmedicineHumansProspective StudiesMenorrhagiabusiness.industryGoserelinObstetrics and GynecologyEndoscopyMiddle AgedSurgeryExact testTreatment OutcomeDelayed-Action PreparationsUterine NeoplasmsGoserelinFemaleAmenorrheamedicine.symptombusinessAdenomyomamedicine.drugHormone
researchProduct

Dosage individualization of erythropoietin using a profile-dependent support vector regression

2003

The external administration of recombinant human erythropoietin is the chosen treatment for those patients with secondary anemia due to chronic renal failure in periodic hemodialysis. The objective of this paper is to carry out an individualized prediction of the EPO dosage to be administered to those patients. The high cost of this medication, its side-effects and the phenomenon of potential resistance which some individuals suffer all justify the need for a model which is capable of optimizing dosage individualization. A group of 110 patients and several patient factors were used to develop the models. The support vector regressor (SVR) is benchmarked with the classical multilayer percept…

AdultAnemia HemolyticInjections SubcutaneousAutoregressive conditional heteroskedasticityBiomedical EngineeringMachine learningcomputer.software_genreCohort StudiesHemoglobinsRenal DialysisFeature (machine learning)HumansMedicineSensitivity (control systems)Time seriesErythropoietinAgedAged 80 and overArtificial neural networkbusiness.industryMiddle AgedRecombinant ProteinsRegressionDrug Therapy Computer-AssistedRegression PsychologySupport vector machineTreatment OutcomeMultilayer perceptronKidney Failure ChronicNeural Networks ComputerArtificial intelligencebusinesscomputerAlgorithmsBiomedical engineeringIEEE Transactions on Biomedical Engineering
researchProduct

The Quest for Predictors of Shunt-Dependent Chronic Hydrocephalus After Aneurysmal Subarachnoid Hemorrhage: Toward a Tailored Approach for Permanent …

2021

AdultAneurysmal subarachnoid hemorrhage Cerebrospinal fluid (CSF) output External ventricular drainage Hydrocephalus Adult Cerebrospinal Fluid Shunts Chronic Disease Aged Humans Hydrocephalus Ventriculoperitoneal Shunt Predictive Value of Tests Middle Aged Subarachnoid Hemorrhage Risk Assessment Prognosis Treatment OutcomeCerebrospinal fluid (CSF) output2019-20 coronavirus outbreakmedicine.medical_specialtySubarachnoid hemorrhageCoronavirus disease 2019 (COVID-19)Aneurysmal subarachnoid hemorrhageSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Risk AssessmentVentriculoperitoneal ShuntPredictive Value of TestsmedicineHumansAgedbusiness.industryExternal ventricular drainageMiddle AgedSubarachnoid Hemorrhagemedicine.diseasePrognosisChronic hydrocephalusCerebrospinal Fluid ShuntsHydrocephalusShunt (medical)SurgeryTreatment OutcomeChronic DiseaseSurgeryNeurology (clinical)businessHydrocephalus
researchProduct

Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRI…

2022

Objective: Post-stroke epilepsy (PSE) is one of the most common causes of acquired epilepsy and accounts for about 10-15% of all newly diagnosed epilepsy cases. However, evidence about the clinical profile of antiseizure medications in the PSE setting is currently limited. Brivaracetam (BRV) is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A. The aim of this study was to assess the 12-month effectiveness and tolerability of adjunctive BRV in patients with PSE treated in a real-world setting. Methods: This was a subgroup analysis of patients with PSE included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). The BRIVAFI…

AdultAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; StrokeCerebrovascular diseasesSettore MED/26Antiseizure medication Brivaracetam Focal seizures Stroke Cerebrovascular diseasesFocal seizuresDouble-Blind MethodDrug TherapySeizuresHumansAgedRetrospective StudiesAntiseizure medicationEpilepsyGeneral MedicineMiddle AgedPyrrolidinonesStrokeTreatment OutcomeNeurologyItalyCombinationBrivaracetamAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; Stroke; Adult; Aged; Anticonvulsants; Double-Blind Method; Drug Therapy Combination; Humans; Italy; Middle Aged; Pyrrolidinones; Retrospective Studies; Seizures; Treatment Outcome; Epilepsy; StrokeDrug Therapy CombinationAnticonvulsantsNeurology (clinical)
researchProduct

Goldmann Tonometry After Hyperopic Laser In Situ Keratomileusis

2004

PURPOSE To identify differences in applanation tonometry between retreated and nonretreated eyes (primary LASIK eyes) 6 months after hyperopic laser in situ keratomileusis. METHODS In a prospective study 100 eyes (100 patients) underwent conventional hyperopic laser in situ keratomileusis under a 160-microm flap. Central Goldmann applanation tonometry was determined before and 6 months after surgery in 78 (78%) primary LASIK eyes and before surgery and 6 months after the retreatment date in 22 (22%) retreated eyes. RESULTS Preoperative mean tonometry was 14.96 +/- 1.96 mm Hg and 15.30 +/- 1.95 mm Hg in primary LASIK and retreated eyes, respectively. Six months after surgery it was 12.99 +/-…

AdultApplanation tonometrymedicine.medical_specialtyIntraocular pressureTime Factorsgenetic structuresmedicine.medical_treatmentKeratomileusis Laser In SitueducationKeratomileusisGoldmann applanation tonometryTonometry OcularmedicineHumansPostoperative PeriodProspective StudiesIntraocular Pressurebusiness.industrySignificant differenceLASIKhumanitieseye diseasesSurgeryGoldmann tonometryOphthalmologyHyperopiaTreatment OutcomeRetreatmentsense organsbusinessCornea
researchProduct

Increased migraine-free intervals with multifocal repetitive transcranial magnetic stimulation.

2021

Introduction: Episodic migraine is a debilitating condition associated with vast impairments of health, daily living, and life quality. Several prophylactic treatments exist, having a moderate ratio of action related to side effects and therapy costs. Repetitive transcranial magnetic stimulation (rTMS) is an evidence based therapy in several neuropsychiatric conditions, showing robust efficacy in alleviating specific symptoms. However, its efficacy in migraine disorders is unequivocal and might be tightly linked to the applied rTMS protocol. We hypothesized that multifocal rTMS paradigm could improve clinical outcomes in patients with episodic migraine by reducing the number of migraine day…

AdultAuramedicine.medical_treatmentMigraine Disorders50% responder RatesBiophysicsStimulationNeurosciences. Biological psychiatry. NeuropsychiatryPilot Projectslaw.inventionRandomized controlled trialDouble-Blind MethodlawmedicineHumansAdverse effectMigraineBalance (ability)business.industryGeneral NeurosciencePreventionMiddle Agedmedicine.diseaseTranscranial Magnetic StimulationTranscranial magnetic stimulationMultifocal rTMSTreatment OutcomeMigraineAnesthesiaPropensity score matchingMigraine daysQuality of LifeFemaleNeurology (clinical)businessRC321-571Brain stimulation
researchProduct